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Abstract: Muscarinic receptors have been implicated in neurological disorders including Alzheimer’s disease, Parkinson’s
disease, and schizophrenia. Nineteen derivatives of thiadiazolyltetrahydropyridine (TZTP), a core that has previously
shown high affinities towards muscarinic receptor subtypes, were synthesized and evaluated via in vitro binding assays.
The title compound, a fluoro-polyethyleneglycol analog of TZTP (4c), was subsequently labelled with fluorine-18. Fluo-
rine-18-labelled 4c was produced, via an automated synthesis, in an average radiochemical yield of 36% (uncorrected for
decay), with high radiochemical purity (>99%) and high specific activity (326 GBq/mmol; end-of-bombardment), within
40 min (n = 3). Ex vivo biodistribution studies following tail-vein injection of [18F]4c in conscious rats displayed sufficient
brain uptake (0.4%–0.7% injected dose / gram of wet tissue in all brain regions at 5 min post injection); however, there
were substantial polar metabolites present in the brain, thereby precluding future use of [18F]4c for imaging in the central
nervous system.
Key words: fluorine-18, muscarinic receptor, thiadiazolyltetrahydropyridine (TZTP), positron emission tomography (PET).
Re´sume´ : Les re´cepteurs muscariniques ont e´te´ implique´s dans des de´sordres neurologiques, dont la maladie d’Alzheimer,
la maladie de Parkinson et la schizophre´nie. On a re´alise´ la synthe`se de dix-neuf de´rive´s de la thiadiazolylte´trahydropyri-
dine (TZTP), un produit fondamental pour lequel des e´tudes ante´rieures ont permis de montrer de grandes affinite´s vis-a`-
vis des sous-types de re´cepteurs muscarinique, et on a e´value´ leurs proprie´te´s par des essais de fixation in vitro. On a sub-
se´quemment marque´ au fluor-18 le compose´ mentionne´ dans le titre (4c), un analogue fluoropolye´thyle`neglycol de la
TZTP. Le compose´ 4c marque´ au fluor-18 a e´te´ obtenu, par le biais d’une synthe`se automatise´e, avec un rendement radio-
chimique de 36 % (non corrige´ pour la de´croissance), avec une purete´ radiochimique e´leve´e (>99 %) et une activite´ spe´ci-
fique e´leve´e (326 GBq/mmol; fin du bombardement), en moins de 40 minutes (n = 3). Des e´tudes de biodistribution ex
vivo a` la suite d’injectons dans la veine de la queue du [18F]4c dans des rats conscients ont de´montre´ qu’il y se produit
une absorption suffisante par le cerveau (0,4 a` 0,7 % de la dose injecte´e / gramme de tissu mouille´ dans toutes les re´gions
du cerveau cinq minutes apre`s l’injection) ; toutefois, plusieurs me´tabolites polaires sont pre´sents dans le cerveau et cette
situation e´limine l’usage dans le futur du [18F]4c pour faire de l’imagerie du syste`me nerveux central.
Mots-cle´s : fluor-18, re´cepteur muscarinique, thiadiazolylte´trahydropyridine (TZTP), tomographie a` e´mission de positon
(TEP).
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Introduction
Muscarinic acetylcholine receptors (mAChRs) are present
in both the peripheral and central nervous system (CNS) and
are responsible for mediating the metabotropic effects of
acetylcholine.1 There are 5 distinct subtypes of the muscar-
inic acetylcholine receptor, M1, M2, M3, M4, and M5, each
having distinct functions and unique distributions in the
CNS.2 The M1 and M2 receptors are abundant in the CNS
and have postulated roles in Alzheimer’s disease and schizo-
phrenia, as well as a range of cognitive disorders.3,4 The M3
and M5 receptors are present in relatively lower concentra-
tions in the CNS.3 M3 receptors have no known correlations
with neuropsychiatric disorders, whereas M5 receptors have
been linked to schizophrenia and addictions.3,4 The M4 re-
ceptor is present in the CNS, particularly in the cortex, stria-
tum, and hippocampus,2,3 and is associated with Parkinson’s
disease and schizophrenia.1,4 The synthesis of subtype-selec-
tive drugs that target mAChRs is an ongoing goal in drug
development. To date, the only clinically approved drugs
that target mAChRs are nonselective antagonists that are
used for treating patients suffering from Parkinson’s disease.
Applying imaging modalities such as single photon emis-
sion computed tomography (SPECT) and positron emission
tomography (PET)5,6 to elucidate the mechanism of action
of new pharmaceuticals targeting muscarinic receptors in
vivo has been of long-standing interest.7 Derivatization of
the thiadiazolyltetrahydropyridine (TZTP) core8 has led to
the development of muscarinic subtype-selective PET radio-
tracers.9–12 The M2-specific agonist radiotracer, fluorine-18
(18F; t1/2 = 109.7 min) labelled fluoropropylthio-TZTP
([18F]FP-TZTP),11,13,14 was proven to be selective through
knockout mice studies15,16 and is currently the only M2-
specific radiotracer established for human PET imaging.17,18
Fluorine-18-labelled FP-TZTP has been used to study risk
factors of ageing19–21 and mood disorders.22,23
Driven largely by the theory that M1 receptor density is
altered in the brain of patients with Alzheimer’s disease in
response to the degeneration of the cholinergic pathway, an-
other TZTP derivative, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-
yl)-1-methyl-1,2,5,6-tetrahydropyridine (xanomeline), was
found to exhibit M1/M4 selectivity.24 While it was found
that xanomeline increased cognitive function of patients
with Alzheimer’s disease, several side effects precluded its
therapeutic use. Carbon-11 (11C; t1/2 = 20.4 min) labelled xa-
nomeline was evaluated in human subjects9,25 and a 18F-
labelled xanomeline derivative was evaluated in rodents25
but neither radiopharmaceutical was further pursued because
of inadequate receptor selectivity.
The present study sought to systematically prepare new
muscarinic receptor subtype-specific TZTP analogs for de-
velopment as PET radiopharmaceuticals. We report the syn-
thesis of hydroxy- and fluoro-alkyl as well as hydroxy- and
fluoro-polyethyleneglycol (PEG) ether and thioether analogs
of TZTP, and the determination of their in vitro binding af-
finities (Ki) towards the five muscarinic subtypes, as well as
s1 and s2 receptors. All analogs synthesized in this work are
amenable to labelling with either 18F or 11C. A promising
fluoro-PEG derivative of TZTP (4c), identified from initial
in vitro screening, was radiolabelled with 18F and evaluated
for its potential to image muscarinic receptors in the rodent
brain.
Results and discussion
Chemistry
The syntheses of 19 derivatives of TZTP (Table 1) are re-
ported, including previously known compounds (2a,13
4a,11,12 8a,26 8b,26 9c,25 and 108). Syntheses of the TZTP
analogs were carried out by literature procedures with mod-
ifications. Thioether-PEG analogs of TZTP, with both fluoro
(4) and hydroxyl (2) groups at the terminal position, were
synthesized as shown in Scheme 1. To conserve the
TZTP core (3-(4-chloro-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-
tetrahydropyridine; 1),8 fluoroalkyl and fluoro-PEG chains
were synthesized from the respective diols (5, Scheme 2)
for subsequent reactions with 1. The diols were disubstituted
with benzyl-protecting and tosyloxy-leaving groups (6). Nu-
cleophilic displacement of the tosyloxy group of 6 with
fluoride resulted in O-benzyl protected fluoroalkyl and
fluoro-PEG chains (7). The hydroxyl analogs (8) were syn-
thesized by reaction of the appropriate diol (5) with 1
(Scheme 3). Scheme 3 shows the synthesis of the desired
fluoro-alkyl and fluoro-PEG ether-TZTP analogs (9), pre-
pared by catalytic hydrogenation of 7 and in situ reaction
with 1 in the presence of sodium hydride (NaH). Several
TZTP derivatives with incorporated PEG groups have been
synthesized in attempts to achieve subtype selectivity and
improve water solubility, binding affinity, and agonist po-
tency toward mAChRs.27,28 The present work further ex-
plores the use of PEG groups as a means of expanding the
series of TZTP derivatives, by replacing alkyl groups with
PEG chains; [18F]fluoro-PEG groups have demonstrated
similar pharmacological advantages when incorporated into
PET radiopharmaceuticals.29 In preparation for in vitro bind-
ing assay studies, all 19 TZTP analogs synthesized in the
present work (Table 1) were characterized by 1H and 19F
(when applicable) NMR spectroscopy, high resolution mass
spectrometry, and elemental analysis (all compounds
were >97% pure by elemental analysis).
In vitro binding assays
The thioether-TZTP derivatives (compounds 2 and 4) as
well as the ether derivatives (compounds 8–10) were eval-
uated by the National Institute of Mental Health’s Psychoac-
tive Drug Screening Program to determine their binding
affinities towards each of the five muscarinic subtypes, as
well as towards s1 and s2 receptors; the s receptors are
known competition sites for ligands targeting mAChRs.30 In
the initial assay, all six thioether-TZTP derivatives (2a–2c
and 4a–4c) were measured for affinity towards the afore-
mentioned receptors (Table S1 in the Supplementary data;
values in parentheses), and a fluoro-PEG derivative of
TZTP with moderate affinity towards the M4 receptor (4c;
Ki = 48 nM) was identified. Based on our initial binding as-
say, we advanced to radiolabelling this compound with
fluorine-18, as it represents the first attempt to develop a
PET radiotracer for imaging the M4 receptor and is a novel
fluorinated-PEG derivative of TZTP. As such, our goal was
van Oosten et al. 1223
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to radiolabel the title compound, 4c, with 18F and evaluate
its potential for imaging the CNS via a preliminary ex vivo
biodistribution study.
Radiochemistry
The radiosynthetic approach for [18F]4c was similar to our
previously reported synthesis for [18F]FP-TZTP,14 where the
appropriate tosyloxy-containing radiolabelling precursor (3c)
was subjected to reaction with fluorine-18-labelled potas-
sium cryptand fluoride (K[18F]/K222) in CH3CN at 90 8C for
10 min (Scheme 4) followed by HPLC purification (Fig. 1).
The formulated product was >99% radiochemically pure
(Fig. 2) and the log D was experimentally determined to be
1.73 ± 0.01 (pH = 7.4), using a previously reported
method.31 The automated synthesis of [18F]4c resulted in a
radiochemical yield of 35.6% ± 15.3% based on [18F]fluoride
and uncorrected for decay in a synthesis time of 37 min (n =
3). The specific activity of [18F]4c was 326 ± 198 GBq/mmol
(corrected to end-of-bombardment). Fluorine-18-labelled 4c
is the first reported 18F-labelled PEG derivative of TZTP.
While the hydroxyl derivatives of TZTP (series 2 and 8) are
not amenable to labelling with 18F, similar compounds have
been readily labelled by reaction of the respective desmethyl
precursors with [11C]CH3I.9,12
Ex vivo biodistribution in rodents
Preliminary ex vivo biodistribution studies using [18F]4c
were subsequently carried out in conscious male Sprague–
Dawley rats.32,33 Fluorine-18-labelled 4c demonstrated fast
and efficient uptake in the rodent brain (0.4%–0.7% injected
dose / gram of wet tissue in all brain regions at 5 min post
injection) following tail-vein injection (Fig. S1 in the Sup-
plementary data). This uptake was followed by a fast wash-
out, with most of the radioactivity cleared from the brain by
15 min. Radio-HPLC analysis of plasma identified a rapid
degradation of the parent compound to both hydrophilic and
lipophilic metabolites. At 15 min after injection of [18F]4c
only 4.5% of the parent compound was unmetabolized.
Analysis of brain homogenates 60 min after injection
(Fig. 3) found that while the parent compound was present
in the brain, there was a significant accumulation of radio-
active polar metabolites (24%). Owing to the presence of ra-
dioactive metabolites in the brain, further studies were not
justified because [18F]4c does not present suitable properties
for imaging the CNS.
Conclusion
We report the synthesis of 13 new TZTP derivatives that
are amenable for radiolabelling with 11C and (or) 18F. Com-
Table 1. General structure and TZTP derivatives synthesized.
1224 Can. J. Chem. Vol. 88, 2010
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pound 4c was chosen as a lead compound for radiolabelling
based on in vitro binding assays and represents the first fluoro-
PEG derivative of TZTP. Automated radiosynthesis of
[18F]4c was achieved with good radiochemical yields, high
specific activity, and excellent radiochemical purity within
40 min. Ex vivo biodistribution studies in rodent models
showed appreciable amounts of polar radioactive metabo-
lites in the brain, suggesting that [18F]4c is not suitable for
further development as a radiopharmaceutical for imaging
the CNS.
Scheme 1. General syntheses of thioether-TZTP derivatives and radiolabelling precursors. (i) 1, Li2S, DMF; 2, bromo- or chloro-alcohol,
K2CO3, DMF. (ii) TsCl, Et3N, DMAP, CH2Cl2. (iii) TBAF, THF.
Scheme 2. General syntheses of benzyl-protected fluoro-alcohols. (i) 1, BnBr, KOH, neat; 2, Et3N, DMAP, TsCl, CH2Cl2. (ii) TBAF, THF,
microwave heating.
Scheme 3. General syntheses of ether-TZTP derivatives. (i) 5a–5f, NaH, THF. (ii) 1, Pd/C, Pd(OH)2, H2(g), THF; 2, NaH, 1, THF.
van Oosten et al. 1225
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Experimental section
General methods
3-Chloro-(pyridine-3-yl)-1,2,5-thiadiazole was purchased
from commercial suppliers and was used as received without
further purification unless otherwise specified. Compound 1,
3-(3-chloro-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methyl-
pyridine,8 and compound 3a, 3-(4-(1-methyl-1,2,5,6-tetra-
hydropyridin-3-yl)-1,2,5-thiadiazol-3-ylthio)propyl-4-methyl-
benzenesulfonate,14 were prepared by literature procedures.
All water used was distilled and deionized and all mobile
phases were made with HPLC-grade solvents. Flash column
chromatography purification was accomplished using silica
gel 60 (63–200 mm, Caledon). Preparative thin-layer chro-
matography (PTLC) was accomplished using silica gel GF
plates (20 cm  20 cm, 2000 mm) from Analtech. All new
compounds were obtained as oils following purification.
High resolution mass spectrometry (HR-MS) was con-
ducted by the Advanced Instrumentation for Molecular
Structure Laboratory or by the Centre for Biological Timing
and Cognition at the University of Toronto. Elemental anal-
ysis (EA) was performed by the Analytical Laboratory for
Environmental Science Research and Training, University
of Toronto. Proton and carbon-13 NMR spectra were re-
corded at 25 8C in CDCl3 on a Varian Mercury 300 MHz
or 400 MHz spectrometer with an autoswitchable H/F/C/P
5 mm probe with gradients. Proton NMR chemical shifts
were reported using either tetramethylsilane (TMS,
0.00 ppm) as an internal standard or referencing to the resid-
ual proton in CDCl3 (7.26 ppm). The proton resonances of
primary alcohols were often not observed owing to ex-
change. For 13C NMR, shifts were referenced to CDCl3
(77.0 ppm). Fluorine-19 NMR shifts were referenced to ex-
ternal CFCl3 (0.00 ppm). Tetrabutylammonium fluoride
(TBAF) was prepared by evaporation of tetrahydrofuran
(THF) from a 1.0 M solution under reduced pressure, and
then drying under reduced pressure overnight, as modified
from a previously reported literature procedure.34 THF was
freshly distilled over lithium aluminum hydride (LiAlH4).
All animal experiments were carried out under humane
conditions, with approval from the Animal Care Committee
at the Centre for Addiction and Mental Health and in ac-
cordance with the guidelines set forth by the Canadian
Council on Animal Care.
Scheme 4. Radiosynthesis of [18F]4c. RCY = radiochemical yield, not corrected for decay.
Fig. 1. Semipreparative HPLC purification (20:80 CH3CN:H2O +
0.1 N ammonium formate + 1% formic acid (pH 4), Semi-Prep
LUNA C18(2) (250 mm  10 mm, 10 mm, l = 254 nm) at 6 mL/
min) of [18F]4c (tR = 13 min).
Fig. 2. Analytical HPLC (Phenomenex Prodigy C18 (ODS prep),
30:70 CH3CN:H2O + 0.1 N ammonium formate; l = 254 nm;
3.0 mL/min) of purified [18F]4c (from top to bottom: gamma, UV
(254 nm), and UV spiked with 4c (254 nm); tR = 3.2 min).
Fig. 3. HPLC analysis (see the Metabolism studies section for
HPLC conditions) of rat brain homogenates at 60 min post injection
of [18F]4c.
1226 Can. J. Chem. Vol. 88, 2010
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Chemical synthesis
3-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-ylthio)propan-1-ol (2a)
Compound 2a was prepared by minor modifications to a
literature procedure.13 Briefly, 250 mg of 1 (1.16 mmol)
was dissolved in 3 mL of anhydrous DMF in an oven-dried
round-bottomed flask under nitrogen. Li2S (2.9 mmol) was
added to the mixture with stirring at 60 8C in an oil bath
for 5 h. Upon consumption of the starting material, the reac-
tion was cooled to room temperature (RT) and 3-bromo-
propanol (2.9 mmol) was added, followed by addition of
K2CO3 (2.9 mmol). The reaction mixture was stirred at RT
for 35 min. Upon completion, the reaction was diluted with
ether (50 mL), washed with H2O (3  50 mL) and brine
(50 mL), dried over NaSO4, and concentrated. PTLC purifi-
cation was performed (20:80 EtOAc:Hex) to yield 217 mg
of 2a (69%). 1H NMR (CDCl3, 300 MHz) d: 6.77–6.71 (m,
1H), 3.71 (t, 3JHH = 5.9 Hz, 2H), 3.45–3.42 (m, 2H), 3.37 (t,
3JHH = 6.9 Hz, 2H), 3.22 (br, 1H), 2.63–2.57 (m, 2H), 2.51–
2.43 (m, 2H), 2.47 (s, 3H), 2.04–1.91 (m, 2H). HR-MS
calcd. for C11H18N3OS2 [M + 1]: 272.0897; found:
272.0885. EA calcd.: C 48.68, H 6.33, N 15.49; found: C
48.39, H 6.46, N 14.90.
2-(2-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-ylthio)ethoxy)ethanol (2b)
The general procedure for the synthesis of 2a was fol-
lowed using 1 (1.16 mmol) in DMF with 2.5 equiv. of Li2S,
2.5 equiv. of 2-(2-chloroethoxy)ethanol, and 2.5 equiv. of
K2CO3 to give 304 mg of 2b (87%) after PTLC purification.
1H NMR (CDCl3, 300 MHz) d: 6.77–6.72 (m, 1H), 3.84 (t,
3JHH = 6.3 Hz, 2H), 3.76–3.72 (m, 2H), 3.64–3.59 (m, 2H),
3.51 (t, 3JHH = 6.3 Hz, 2H), 3.45–3.42 (m, 2H), 2.63–2.57
(m, 2H), 2.52–2.44 (m, 2H), 2.46 (s, 3H). HR-MS calcd. for
C12H20N3O2S2 [M + 1]: 302.0991; found: 302.0990. EA
calcd.: C 47.81, H 6.37, N 13.94: found: C 47.92, H 6.32,
N 13.60.
2-(2-(2-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-ylthio)ethoxy)ethoxy)ethanol (2c)
The general procedure for the synthesis of 2a was fol-
lowed using 1 (1.16 mmol) in DMF with 2.5 equiv. of Li2S,
2.5 equiv. of 2-(2-(2-chloroethoxy)ethoxy)ethanol, and
2.5 equiv. of K2CO3. After PTLC purification, 2c was ob-
tained in a 95% yield (542 mg). 1H NMR (CDCl3,
300 MHz) d: 6.77–6.71 (m, 1H), 3.83 (m, 2H), 3.75–3.71
(m, 2H), 3.69–3.66 (m, 4H), 3.63–3.59 (m, 2H), 3.51 (t,
3JHH = 6.5 Hz, 2H), 3.45–3.42 (m, 2H), 2.63–2.59 (m, 2H),
2.52–2.45 (m, 2H), 2.46 (s, 3H). HR-MS calcd. for
C14H24N3O3S2 [M + 1]: 346.1253; found: 346.1266. EA
calcd.: C 48.67, H 6.72, N 12.17; found: C 47.64, H 6.88,
N 11.83
2-(2-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-ylthio)ethoxy)ethyl 4-methylbenzenesulfonate
(3b)
Compound 3b was made by an analogous procedure to
that of compound 3a.14 Briefly, 267 mg (0.89 mmol) of 2b
was dissolved in 8 mL of CH2Cl2 followed by the addition
of 1.5 equiv. of p-toluenesulfonyl chloride (TsCl), 3 equiv.
of triethylamine (TEA), and a catalytic amount of dimethy-
laminopyridine (DMAP; 1 mol%). Compound 3b was ob-
tained in an 86% yield (348 mg). 1H NMR (CDCl3,
300 MHz) d: 7.82–7.76 (m, 2H), 7.35–7.29 (m, 2H), 6.75–
6.70 (m, 1H), 4.19–4.14 (m, 2H), 3.74 (t, 3JHH = 6.3 Hz,
2H), 3.71–3.66 (m, 2H), 3.44–3.36 (m, 4H), 2.62–2.56 (m,
2H), 2.51–2.42 (m, 8H).
2-(2-(2-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-ylthio)ethoxy)ethoxy)ethyl 4-
methylbenzenesulfonate (3c)
Compound 3c was made by an analogous procedure to
that of compound 3a.14 Briefly, 350 mg (1.01 mmol) of 2c
was dissolved in 8 mL of CH2Cl2 followed by the addition
of 1.5 equiv. of TsCl, 3 equiv. of TEA, and catalytic
DMAP (1 mol%). Compound 3c was obtained in a 72%
yield (352 mg). 1H NMR (CDCl3, 400 MHz) d: 7.82–7.78
(m, 2H), 7.65–7.31 (m, 2H), 6.77–6.73 (m, 1H), 4.18–4.15
(m, 2H), 3.79 (t, 2JHF = 6.4 Hz, 2H), 3.71–3.68 (m, 2H),
3.61–3.59 (m, 4H), 3.48 (t, 3JHH = 6.6 Hz, 2H), 3.44–3.42
(m, 2H), 2.62–2.58 (m, 2H), 2.49–2.43 (m, 8H).
3-(4-(3-Fluoropropylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-
1,2,5,6-tetrahydropyridine (4a)
Compound 4a was prepared by modifications to the liter-
ature procedures.11,13 To an oven-dried round-bottomed flask
containing 4.9 mmol TBAF (dried under reduced pressure
overnight) was added 10 mL of freshly distilled THF, fol-
lowed by 0.33 mmol of 3a. The reaction was refluxed for
3 h and then diluted with 50 mL H2O and washed with
50 mL of EtOAc (2). The combined organic layer was
washed with 50 mL of brine, dried over Na2SO4, and con-
centrated. The product was purified using PTLC (7:93
MeOH:CH2Cl2) to yield 37 mg of 4a (36%). 1H NMR
(CDCl3, 300 MHz) d: 6.70–6.65 (m, 1H), 4.52 (dt, 2JHF =
47.1 Hz, 3JHH = 5.6 Hz, 2H), 3.39–3.35 (m, 2H), 3.33 (t,
3JHH = 7.22 Hz, 2H), 2.56–2.49 (m. 2H), 2.44–2.37 (m,
2H), 2.39 (s, 3H), 2.12 (dm, 3JHF = 26.5 Hz, 2H). 19F NMR
(CDCl3, 282 MHz) d: –221.51 (tt, 2JHF = 47.2 Hz, 3JHF =
26.5 Hz). HR-MS calcd. for C11H16FN3S2 [M]: 273.0770;
found: 273.0772. EA calcd.: C 48.32, H 5.91, N 15.37;
found: C 48.23, H 6.03, N 15.12.
3-(2-(2-Fluoroethoxy)ethylthio)-4-(1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)-1,2,5-thiadiazole (4b)
Compound 4b was prepared in an analogous manner to
that of 4a. Briefly, 0.3 mmol of 3b in THF was reacted
with 5 equiv. of TBAF. 4b was obtained in a 33% yield
(36 mg). 1H NMR (CDCl3, 300 MHz) d: 6.79–6.75 (m, 1H),
4.57 (dm, 2JHF = 47.6 Hz, 2H), 3.86 (t, 3JHH = 6.43 Hz, 2H),
3.76 (dm, 3JHF = 29.5 Hz, 2H), 3.52 (t, 3JHH = 6.6 Hz, 2H),
3.49–3.45 (m, 2H), 2.66–2.61 (m, 2H), 2.53–2.47 (m, 2H),
2.48 (s, 3H). 19F NMR (CDCl3, 282 MHz) d: –223.36 (tt,
2JHF = 47.6 Hz, 3JHF = 29.5 Hz). HR-MS calcd. for
C12H19FN3OS2 [M + 1]: 304.0948; found: 304.0950. EA
calcd.: C 47.50, H 5.99, N 13.85; found: C 47.67, H 6.11,
N 13.35.
3-(2-(2-(2-Fluoroethoxy)ethoxy)ethylthio)-4-(1-methyl-
1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole (4c)
Compound 4c was prepared in an analogous manner to
that of 4a. Briefly, 150 mg (0.3 mmol) of 3c was used in
THF (0.1 M) with 5 equiv. of TBAF. 4c was obtained in a
van Oosten et al. 1227
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29% yield (31 mg). 1H NMR (CDCl3, 300 MHz) d: 6.80–
6.75 (m, 1H), 4.56 (dm, 2JHF = 47.8 Hz, 2H), 3.87–3.79 (m,
3H), 3.73–3.68 (m, 5H), 3.54–3.46 (m, 4H), 2.68–2.62 (m,
2H), 2.54–2.47 (m, 2H), 2.49 (s, 3H). 19F NMR (CDCl3,
282 MHz) d: –223.31 (tt, 2JHF = 47.9 Hz, 3JHF = 29.6 Hz).
HR-MS calcd. for C14H23FN3O2S2 [M + 1]: 348.1210;
found: 348.1212. EA calcd.: C 48.39, H 6.39, N 12.10;
found: C 49.07, H 6.74, N 11.66.
3-(Benzyloxy)propyl-4-methylbenzenesulfonate (6a)
To an oven-dried round-bottomed flask under an atmos-
phere of N2 was added propane-1,3-diol (5a, 0.11 mol),
1.4 mL (0.01 mol) of benzyl bromide, and KOH (0.02 mol,
neat). The reaction proceeded at RT. Upon consumption of
benzyl bromide (monitored by TLC, 40:60 EtOAc:Hex), the
reaction mixture was diluted with 50 mL of H2O and
washed with CH2Cl2 (50 mL  2). The combined organic
layers were washed with 50 mL of brine, dried over
Na2SO4, and concentrated. CH2Cl2 (50 mL) was added and
the mixture was cooled on ice. Triethylamine (0.05 mol)
and DMAP (1 mol%) were added. After 10 min of stirring,
0.03 mol of TsCl was added and the reaction proceeded un-
til completion, as monitored by TLC (40:60 EtOAc:Hex).
The mixture was then cooled on ice, diluted with 100 mL
H2O, and washed with dichloromethane (100 mL  2). The
combined organic layers were washed with 100 mL of brine,
dried over Na2SO4, and concentrated. The final product was
purified by flash chromatography (40:60 EtOAc:Hex) to
yield 2.40 g of 6a (75%). 1H NMR (CDCl3, 300 MHz) d:
7.81–7.76 (m, 2H), 7.35–7.22 (m, 7H), 4.40 (s, 2H), 4.17 (t,
3JHH = 6.3 Hz, 2H), 3.50 (t, 3JHH = 5.8, 2H), 2.42 (s, 3H),
1.98–1.90 (q, 3JHH = 6.0 Hz, 2H).
5-(Benzyloxy)pentyl-4-methylbenzenesulfonate (6b)
Compound 6b was prepared in an analogous manner to
that of 6a. Briefly, 0.07 mol of pentane-1,5-diol (5b),
0.02 mol of benzyl bromide, and 0.055 mol of KOH were
used. Following the workup of the reaction mixture, 10 mL
of dichloromethane, 0.07 mol of triethylamine, catalytic
DMAP (1 mol%), and 0.035 mol of TsCl were reacted and
purified (vide supra). Compound 6b was obtained in a 65%
yield (4.54 g). 1H NMR (CDCl3, 300 MHz) d: 7.81–7.76 (m,
2H), 7.36–7.26 (m, 7H), 4.47 (s, 2H), 4.02 (t, 3JHH = 6.3 Hz,
2H), 3.42 (t, 3JHH = 6.6 Hz, 2H), 2.44 (s, 3H), 1.71–1.61 (m,
2H), 1.60–1.51 (m, 2H), 1.46–1.36 (m, 2H).
6-(Benzyloxy)hexyl-4-methylbenzenesulfonate (6c)
Compound 6c was prepared in an analogous manner to
that of 6a. Briefly, 0.06 mol of hexane-1,6-diol (5c),
0.02 mol of benzyl bromide, and 0.055 mol of KOH were
used. Following the workup, 10 mL of dichloromethane,
0.07 mol of triethylamine, DMAP (1 mol%), and 0.04 mol
of TsCl were reacted and purified (vide supra). Compound
6c was obtained in a 61% yield (4.40 g). 1H NMR (CDCl3,
300 MHz) d: 7.81–7.76 (m, 2H), 7.36–7.28 (m, 7H), 4.48 (s,
2H), 4.01 (t, 3JHH = 6.6 Hz, 2H), 3.43 (t, 3JHH = 6.6 Hz,
2H), 2.44 (s, 3H) 1.67–1.51 (m, 4H), 1.35–1.28 (m, 4H).
7-(Benzyloxy)heptyl-4-methylbenzenesulfonate (6d)
Compound 6d was prepared in an analogous manner to
that of 6a. Briefly, 0.02 mol of hexane-1,6-diol (5d),
0.008 mol of benzyl bromide, and 0.015 mol of KOH were
used. After workup, 8 mL of CH2Cl2, 0.025 mol of triethyl-
amine, DMAP (1 mol%), and 0.02 mol of TsCl were reacted
and purified (vide supra). 6d was obtained in a 69% yield
(2.06 g). 1H NMR (CDCl3, 300 MHz) d: 7.81–7.76 (m, 2H),
7.36–7.25 (m, 7H), 4.49 (s, 2H), 4.01 (t, 3JHH = 6.4 Hz, 2H),
3.44 (t, 3JHH = 6.7 Hz, 2H), 2.44 (s, 3H), 1.66–1.51 (m, 4H),
1.36–1.20 (m, 6H).
2-(2-(Benzyloxy)ethoxy)ethyl-4-methylbenzenesulfonate
(6e)
Compound 6e was prepared in an analogous manner to
that of 6a. Diethyleneglycol (5e; 0.03 mol), 0.008 mol of
benzyl bromide, and 0.03 mol of KOH were used. After
workup, 20 mL of dichloromethane, 0.02 mol of triethyl-
amine, DMAP (1 mol%), and 0.07 mol of TsCl were reacted
and purified (vide supra). Compound 6e was obtained in a
43% yield (1.24 g). 1H NMR (CDCl3, 300 MHz) d: 7.81–
7.76 (m, 2H), 7.35–7.26 (m, 7H), 4.53 (s, 2H), 4.19–4.14
(m, 2H), 3.72–3.67 (m, 2H), 3.63–3.59 (m, 2H), 3.58–3.54
(m, 2H), 2.42 (s, 3H).
2-(2-(2-(Benzyloxy)ethoxy)ethoxy)ethyl-4-
methylbenzenesulfonate (6f)
Compound 6f was prepared in an analogous manner to
that of 6a. Briefly, 0.04 mol of diethyleneglycol (5f),
0.01 mol of benzyl bromide, and 0.04 mol of KOH were
used. Following the workup, 20 mL of dichloromethane,
0.02 mol of triethylamine, DMAP (1 mol%), and 0.06 mol
of TsCl were reacted and purified (vide supra). Compound
6f was obtained in a 35% yield (1.40 g). 1H NMR (CDCl3,
300 MHz) d: 7.81–7.76 (m, 2H), 7.35–7.26 (m, 7H), 4.55 (s,
2H), 4.17–4.12 (m, 2H), 3.70–3.66 (m, 2H), 3.65–3.60 (m,
4H), 3.59 (s, 4H), 3.04 (s, 3H).
((3-Fluoropropoxy)methyl)benzene (7a)
To a glass vial (Biotage) under an atmosphere of N2 con-
taining 0.02 mol of TBAF (dried under reduced pressure
overnight) was added 20 mL of freshly distilled THF fol-
lowed by 500 mg (1.6 mmol) of 6a. The reaction was sealed
and microwave heated for 1 h at 160 8C. THF was removed
under reduced pressure and the resulting product was dis-
solved in 50 mL of EtOAc and washed with 50 mL of H2O.
The aqueous layer was washed a second time with 50 mL of
EtOAc and the combined organic layers were washed with
50 mL of brine, dried over Na2SO4, and concentrated.
The product was purified by flash chromatography (30:70
EtOAc:Hex (v/v)) to yield 179 mg of 7a (68%). 1H NMR
(CDCl3, 400 MHz) d: 7.37–7.25 (m, 5H), 4.56 (dt, 2JHF =
47.1 Hz, 3JHH = 6.0 Hz, 2H), 4.51 (s, 2H), 3.60 (t, 3JHH =
6.2 Hz, 2H), 1.99 (dm, 3JHF = 25.8 Hz, 2H). 19F NMR
(CDCl3, 376 MHz) d: –222.05 (tt, 2JHF = 47.0 Hz, 3JHF =
25.7 Hz).
((5-Fluoropentyloxy)methyl)benzene (7b)
Compound 7b was prepared in an analogous manner to
that of 7a, where 0.02 mol of TBAF and 1.4 mmol of 6b
were used in 20 mL of THF. Compound 7b was obtained in
a 70% yield (198 mg). 1H NMR (CDCl3, 400 MHz) d: 7.35–
7.25 (m, 5H), 4.50 (s, 2H), 4.43 (dt, 2JHF = 47.4 Hz, 3JHH =
6.1 Hz, 2H), 3.48 (t, 3JHH = 6.5 Hz, 2H), 1.78–1.62 (m, 4H),
1.54–1.45 (m, 2H). 19F NMR (CDCl3, 376 MHz) d: –218.66
(tt, 2JHF = 47.4 Hz, 3JHF = 24.8 Hz).
1228 Can. J. Chem. Vol. 88, 2010
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((6-Fluorohexyloxy)methyl)benzene (7c)
Compound 7c was prepared in an analogous manner to
that of 7a, where 0.02 mol of TBAF and 1.4 mmol of 6c
were used in 20 mL of THF. Compound 7c was obtained in
a 72% yield (209 mg). 1H NMR (CDCl3, 400 MHz) d: 7.35–
7.24 (m, 5H), 4.50 (s, 2H), 4.42 (dt, 2JHF = 47.4 Hz, 3JHH =
6.2 Hz, 2H), 3.47 (t, 3JHH = 6.6 Hz, 2H), 1.76–1.59 (m, 4H),
1.45–1.39 (m, 4H). 19F NMR (CDCl3, 376 MHz) d: –218.55
(tt, 2JHF = 47.3 Hz, 3JHF = 24.9 Hz).
((7-Fluoroheptyloxy)methyl)benzene (7d)
Compound 7d was prepared in an analogous manner to
that of 7a, where 0.02 mol of TBAF and 1.3 mmol of 6d
were used in 20 mL of THF. Compound 7d was obtained in
an 85% yield (251 mg). 1H NMR (CDCl3, 400 MHz) d:
7.35–7.24 (m, 5H), 4.50 (s, 2H), 4.42 (dt, 2JHF = 47.5 Hz,
3JHH = 6.1 Hz, 2H), 3.46 (t, 3JHH = 6.6 Hz, 2H), 1.75–1.58
(m, 4H), 1.45–1.30 (m, 6H). 19F NMR (CDCl3, 376 MHz)
d: –218.46 (tt, 2JHF = 47.5 Hz, 3JHF = 24.9 Hz).
((2-(2-Fluoroethoxy)ethoxy)methyl)benzene (7e)
Compound 7e was prepared in an analogous manner to
that of 7a, where 0.02 mol of TBAF and 1.4 mmol of 6e
were used in 20 mL of THF. Compound 7e was obtained in
a 91% yield (252 mg). 1H NMR (CDCl3, 400 MHz) d: 7.36–
7.25 (m, 5H), 4.58 (s, 2H), 4.56 (dm, 2JHF = 47.7 Hz, 2H),
3.80–3.78 (m, 1H), 3.73–3.69 (m, 3H), 3.67–3.63 (m, 2H).
19F NMR (CDCl3, 376 MHz) d: –223.27 (tt, 2JHF = 47.7 Hz,
3JHF = 29.4 Hz).
((2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)methyl)benzene (7f)
Compound 7f was prepared in an analogous manner to
that of 7a, where 0.02 mol of TBAF and 1.3 mmol of 6f
were used in 20 mL of THF. Compound 7f was obtained in
a 90% yield (273 mg). 1H NMR (CDCl3, 400 MHz) d: 7.36–
7.26 (m, 5H), 4.57 (s, 2H), 4.55 (dm, 2JHF = 47.6 Hz, 2H),
3.80–3.77 (m, 1H), 3.72–3.67 (m, 7H), 3.66–3.62 (m, 2H).
19F NMR (CDCl3, 376 MHz) d: –223.34 (tt, 2JHF = 47.7 Hz,
3JHF = 29.8 Hz).
3-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-yloxy)propan-1-ol (8a)
To an oven-dried round-bottomed flask under an atmos-
phere of N2, 1.16 mmol of propane-1,3-diol (5a) was added
to 2.5 mL of freshly distilled THF. To the reaction mixture
was added 0.92 mmol of 60% NaH, and the mixture was
stirred at RT for 30 min. Compound 1 (0.23 mmol) was
added and the reaction was refluxed overnight. The reaction
mixture was diluted with 30 mL of H2O and washed with
30 mL of CH2Cl2 (2). The combined organic layers were
then washed with 40 mL of brine, dried over Na2SO4, and
concentrated. The product was purified by PTLC (30:70
EtOAc:Hex (v/v)) and 8a was obtained in a yield of
25.2 mg (43%). 1H NMR (CDCl3, 400 MHz) d: 7.04–7.00
(m, 1H), 4.59 (t, J = 6.1 Hz, 2H), 3.78 (t, J = 6.1 Hz, 2H),
3.46–3.44 (m, 2H), 2.60–2.56 (m, 2H), 2.47–2.42 (m, 2H),
2.46 (s, 3H), 2.11–2.04 (m, 2H). HR-MS calcd. for
C11H18N3O2S [M + 1]: 256.1114; found: 256.1112. EA
calcd.: C 51.74, H 6.71, N 16.46; found: C 51.72, H 6.73,
N 16.06.
4-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-yloxy)butan-1-ol (8b)
Compound 8b was prepared in an analogous manner to
that of 8a, where 1.15 mmol of butane-1,4-diol (5b),
0.92 mmol of 60% NaH, and 0.23 mmol of 1 in 2.5 mL of
freshly distilled THF were used. Compound 8b was obtained
in a 48% yield (30 mg). 1H NMR (CDCl3, 300 MHz) d:
7.07–7.02 (m, 1H), 4.48 (t, 3JHH = 4.46 Hz, 2H), 3.71 (t,
3JHH = 6.44 Hz, 2H), 3.47–3.42 (m, 2H), 2.61–2.55 (m,
2H), 2.48–2.41 (m, 2H), 2.46 (s, 3H), 2.00–1.89 (m, 2H),
1.78–1.67 (m, 2H). HR-MS calcd. for C12H20N3O2S [M +
1]: 270.1271; found: 270.1269. EA calcd.: C 53.51, H 7.11,
N 15.60; found: C 52.56, H 6.85, N 15.49.
5-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-yloxy)pentan-1-ol (8c)
Compound 8c was prepared in an analogous manner to
that of 8a, where 1.15 mmol of pentane-1,5-diol (5c),
0.92 mmol of 60% NaH, and 0.23 mmol of 1 in 2.5 mL of
freshly distilled THF were used. Compound 8c was obtained
in a 34% yield (22 mg). 1H NMR (CDCl3, 300 MHz) d:
7.07–7.02 (m, 1H), 4.47 (t, 3JHH = 6.54 Hz, 2H), 3.69 (t,
3JHH = 6.42 Hz, 2H), 3.48–3.43 (m, 2H), 2.61–2.55 (m,
2H), 2.49–2.42 (m, 2H), 2.47 (s, 3H), 1.95–1.83 (m, 2H),
1.70–1.51 (m, 4H). HR-MS calcd. for C13H22N3O2S [M +
1]: 284.1427; found: 284.1425. EA calcd.: C 55.10, H 7.47,
N 14.83; found: C 58.85, H 7.07, N 14.82.
6-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-yloxy)hexan-1-ol (8d)
Compound 8d was prepared in an analogous manner to
that of 8a, where 1.15 mmol of hexane-1,6-diol (5d),
0.92 mmol of NaH (60% in mineral oil), and 0.23 mmol of
1 in 2.5 mL of freshly distilled THF were used. Compound
8d was obtained in a 25% yield (17 mg). 1H NMR (CDCl3,
300 MHz) d: 7.07–7.01 (m, 1H), 4.49–4.41 (m, 2H), 3.67–
3.60 (m, 2H), 3.48–3.40 (m, 2H), 2.62–2.55 (m, 2H), 2.51–
2.42 (m, 2H), 2.47 (s, 3H), 2.14 (br, 1H), 1.91–1.80 (m, 2H),
1.65–1.54 (m, 2H), 1.53–1.39 (m, 4H). HR-MS calcd. for
C14H24N3O2S [M + 1]: 298.1584; found: 298.1582. EA
calcd.: C 56.54, H 7.79, N 13.75; found: C 55.02, H 7.42,
N 13.75.
2-(2-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-yloxy)ethoxy)ethanol (8e)
Compound 8e was prepared in an analogous manner to
that of 8a, where 0.084 mmol of diethyleneglycol (5e),
0.42 mmol of 60% NaH, and 0.46 mmol of 1 in 3 mL of
freshly distilled THF were used. Compound 8e was obtained
in a 74% yield (89 mg). 1H NMR (CDCl3, 400 MHz) d:
7.08–7.04 (m, 1H), 4.64–4.60 (m, 2H), 3.92–3.89 (m, 2H),
3.76–3.73 (m, 2H), 3.67–3.63 (m, 2H), 3.46–3.43 (m, 2H),
2.59–2.55 (m, 2H), 2.47–2.42 (m, 2H), 2.45 (s, 3H). HR-
MS calcd. for C12H20N3O3S [M + 1]: 286.1220; found:
286.1218. EA calcd.: C 50.50, H 6.72, N 14.73; found: C
49.91, H 6.70, N 14.37.
2-(2-(2-(4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-
thiadiazol-3-yloxy)ethoxy)ethoxy)ethanol (8f)
Compound 8f was prepared in an analogous manner to
that of 8a, where 0.084 mmol of diethyleneglycol (5f),
0.42 mmol of 60% NaH, and 0.46 mmol of 1 in 3.0 mL of
van Oosten et al. 1229
Published by NRC Research Press
Ca
n.
 J.
 C
he
m
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
Pe
ki
ng
 U
ni
ve
rs
ity
 o
n 
06
/0
3/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
 
freshly distilled THF were used. 8f was obtained in a 65%
yield (81 mg). 1H NMR (CDCl3, 400 MHz) d: 6.77–6.73
(m, 1H), 3.85–3.80 (m, 2H), 3.75–3.71 (m, 2H), 3.69–3.66
(m, 4H), 3.63–3.59 (m, 2H), 3.53–3.49 (m, 2H), 3.45–3.42
(m, 2H), 2.63–2.58 (m, 2H), 2.51–2.45 (m, 2H), 2.42 (s,
3H). HR-MS: calcd. for C14H24N3O4S [M + 1]: 330.1482;
found: 330.1476. EA calcd.: C 51.04, H 7.04, N 12.76;
found: C 50.07, H 6.89, N 12.52.
3-(3-Fluoropropoxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-
3-yl)-1,2,5-thiadiazole (9a)
To an oven-dried round-bottomed flask under an atmos-
phere of N2 containing 3 mL of freshly distilled THF was
added 0.5 mmol of 7a followed by 10 mg each of Pd/C and
Pd(OH)2. The reaction vessel was purged with H2(g) and
maintained under an atmosphere of H2(g) for 2 h while stir-
ring vigorously. Upon consumption of the starting material
as monitored by TLC (60:40 EtOAc:Hex (v/v)), the reaction
mixture was purged with N2 and cooled in an ice bath, and
1.0 mmol of NaH (60% in mineral oil) was added. The mix-
ture was stirred for 30 min at RT followed by the addition
of 0.2 mmol of 1. The reaction mixture was subsequently re-
fluxed overnight. Upon consumption of the starting material,
the reaction was filtered through celite and the THF was re-
moved under reduced pressure. The product was dissolved
in 30 mL of CH2Cl2 and washed with 30 mL of H2O, and
the aqueous layer was further extracted with 30 mL of
CH2Cl2. The combined organic layers were washed with
30 mL of brine, dried over Na2SO4, and concentrated. The
product was purified by PTLC (60:40 EtOAc:Hex (v/v)) to
yield 21 mg 9a (41%). 1H NMR (CDCl3, 400 MHz) d:
7.04–6.99 (m, 1H), 4.63 (dm, 2JHF = 47.0 Hz, 2H), 4.61 (t,
3JHH = 6.2 Hz, 2H), 3.47–3.43 (m, 2H), 2.60–2.55 (m, 2H),
2.48–2.42 (m, 2H), 2.46 (s, 3H), 2.25 (dm, 3JHF = 25.6 Hz,
2H). 19F NMR (CDCl3, 376 MHz) d: –222.38 (tt, 2JHF =
47.0 Hz, 3JHF = 25.8 Hz). HR-MS calcd. for C11H17FN3OS
[M + 1]: 258.1071; found: 258.1068. EA calcd.: C 51.34, H
6.27, N 16.33; found: C 51.64, H 6.27, N 15.84.
3-(5-Fluoropentyloxy)-4-(1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)-1,2,5-thiadiazole (9b)
Compound 9b was prepared in an analogous manner to
that of 9a, where 0.4 mmol of 7b was used followed by
1.4 mmol of 60% NaH and 0.23 mmol of 1. Compound 9b
was obtained in a 29% yield (19 mg). 1H NMR (CDCl3,
400 MHz) d: 7.07–7.03 (m, 1H), 4.48 (dt, 2JHF = 46.9 Hz,
3JHH = 6.1 Hz, 2H), 4.47 (t, 3JHH = 6.5 Hz, 2H), 3.50–3.47
(m, 2H), 2.64–2.59 (m, 2H), 2.50–2.44 (m, 2H), 2.49 (s,
3H), 1.94–1.86 (m, 2H), 1.85–1.72 (m, 2H), 1.64–1.56 (m,
2H). 19F NMR (CDCl3, 376 MHz) d: –219.18 (tt, 2JHF =
47.1 Hz, 3JHF = 25.4 Hz). HR-MS calcd. for C13H21FN3OS
[M + 1]: 286.1384; found: 286.1380. EA calcd.: C 54.71, H
7.06, N 14.72; found: C 54.90, H 6.87, N 14.79.
3-(6-Fluorohexyloxy)-4-(1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)-1,2,5-thiadiazole (9c)
Compound 9c was prepared in an analogous manner to
that of 9a, where 0.4 mmol of 7c was used followed by
1.4 mmol of 60% NaH and 0.23 mmol of 1. Compound 9c
was obtained in a 39% yield (27 mg). 1H NMR (CDCl3,
400 MHz) d: 7.07–7.03 (m, 1H), 4.46 (t, 3JHH = 6.9 Hz,
2H), 4.46 (dt, 2JHF = 47.2 Hz, 3JHH = 6.0 Hz, 2H), 3.48–
3.45 (m, 2H), 2.61–2.56 (m, 2H), 2.48–2.43 (m, 2H), 2.47
(s, 3H), 1.90–1.83 (m, 2H), 1.79–1.68 (m, 2H), 1.53–148
(m, 4H). 19F NMR (CDCl3, 376 MHz) d: –218.79 (tt, 2JHF =
47.2 Hz, 3JHF = 25.3 Hz). HR-MS calcd. for C14H23FN3OS
[M + 1]: 300.1540; found: 300.1536. EA calcd.: C 56.16, H
7.41, N 14.03; found: C 56.58, H 7.39, N 13.77.
3-(7-Fluoroheptyloxy)-4-(1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)-1,2,5-thiadiazole (9d)
Compound 9d was prepared in an analogous manner to
that of 9a, where 0.4 mmol of 7d was used followed by
1.4 mmol of 60% NaH and 0.23 mmol of 1. Compound 9d
was obtained in a 35% yield (25 mg). 1H NMR (CDCl3,
400 MHz) d: 7.08–7.04 (m, 2H), 4.45 (t, 3JHH = 6.6 Hz,
2H), 4.45 (dt, 2JHF = 47.6 Hz, 3JHH = 6.2 Hz, 2H), 3.47–344
(m, 2H), 2.61–2.56 (m, 2H), 2.48–2.43 (m, 2H), 2.47 (s,
3H), 1.89–1.81 (m, 2H), 1.76–1.62 (m, 2H), 1.51–1.40 (m,
5H). 19F NMR (CDCl3, 376 MHz) d: –218.62 (tt, 2JHF =
47.5 Hz, 3JHF = 25.2 Hz). HR-MS calcd. for C15H25FN3OS
[M + 1]: 314.1697; found: 314.1693. EA calcd.: C 57.48, H
7.72, N 13.41; found: C 57.69, H 7.65, N 13.17.
3-(2-(2-Fluoroethoxy)ethoxy)-4-(1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)-1,2,5-thiadiazole (9e)
Compound 9e was prepared in an analogous manner to
that of 9a, where 0.4 mmol of 7e was used followed by
1.4 mmol of 60% NaH and 0.23 mmol of 1. Compound 9e
was obtained in a 45% yield (30 mg). 1H NMR (CDCl3,
400 MHz) d: 7.12–7.07 (m, 1H), 4.64–4.61 (m, 2H), 4.58
(dm, 2JHF = 47.6 Hz, 2H), 3.96–3.92 (m, 2H), 3.79 (dm,
3JHF = 29.4 Hz, 2H), 3.47–3.44 (m, 2H), 2.60–2.55 (m, 2H),
2.49–2.43 (m, 2H), 2.46 (s, 3H). 19F NMR (CDCl3,
376 MHz) d: –223.51 (tt, 2JHF = 47.7 Hz, 3JHF = 28.9 Hz).
HR-MS calcd. for C12H19FN3O2S [M + 1]: 288.1177; found:
288.1173. EA calcd.: C 50.16, H 6.361, N 14.62; found: C
50.25, H 6.44, N 14.40.
3-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-4-(1-methyl-
1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole (9f)
Compound 9f was prepared in an analogous manner to
that of 9a, where 0.4 mmol of 7f was used followed by
1.4 mmol of 60% NaH and 0.23 mmol of 1. Compound 9f
was obtained in a 62% yield (46 mg). 1H NMR (CDCl3,
400 MHz) d: 7.11–7.07 (m, 1H), 4.63–4.60 (m, 3H), 4.51–
4.48 (m, 1H), 3.93–3.90 (m, 2H), 3.79–3.77 (m, 1H), 3.74–
3.68 (m, 5H), 3.47–3.45 (m, 2H), 3.60–3.56 (m, 2H), 2.47–
2.43 (m, 2H), 2.46 (s, 3H). 19F NMR (CDCl3, 376 MHz)
d: –223.30 (tt, 2JHF = 47.7 Hz, 3JHF = 29.5 Hz). HR-MS
calcd. for C14H23FN3O3S [M + 1]: 332.1439; found:
332.1434. EA calcd.: C 50.74, H 6.69, N 12.68; found: C
50.87, H 6.75, N 12.86.
3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-
1,2,5-thiadiazole (10)
To an oven-dried round-bottomed flask, 71 mg
(0.7 mmol) of 1-hexanol was added to 3 mL of freshly dis-
tilled THF. To the reaction mixture was added 34 mg
(1.4 mmol) of 95% NaH, and the mixture was allowed to
stir at RT for 30 min. Compound 1 (0.35 mmol) was subse-
quently added and the reaction was refluxed overnight. The
reaction was diluted with 30 mL of H2O and washed with
1230 Can. J. Chem. Vol. 88, 2010
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30 mL of CH2Cl2 (2). The combined organic layers were
then washed with 40 mL of brine, dried over Na2SO4, and
concentrated. The product was purified by PTLC (30:70
EtOAc:Hex (v/v)) and 9 was obtained in a yield of 58 mg
(60%). 1H NMR (CDCl3, 300 MHz) d: 7.09–7.04 (m, 1H),
4.47–4.41 (m, 2H), 3.48–3.43 (m, 2H), 2.61–2.55 (m, 2H),
2.49–2.42 (m, 5H), 1.89–1.78 (m, 2H), 1.52–1.39 (m, 2H),
1.38–1.31 (m, 4H), 0.94–0.87 (m, 3H). HR-MS calcd. for
C14H24N3OS [M + 1]: 282.1635; found: 282.1633. EA
calcd.: C 59.75, H 8.24, N 14.93; found: C 59.68, H 8.14,
N 14.67.
In vitro binding assays
All Ki determinations were conducted by the National In-
stitute of Mental Health’s Psychoactive Drug Screening Pro-
gram (NIMH PDSP), contract No. NO1MH32004. The
NIMH PDSP is directed by Bryan L. Roth, M.D., Ph.D., at
the University of North Carolina at Chapel Hill and Project
Officer Jamie Driscol at NIMH, Bethesda, Maryland, USA
(http://pdsp.med.unc.edu/).
Radiochemical synthesis
Synthesis of [18F]-3-(2-(2-(2-
fluoroethoxy)ethoxy)ethylthio)-4-(1-methyl-1,2,5,6-
tetrahydropyridin-3-yl)-1,2,5-thiadiazole ([18F]4c)
A Scanditronix MC 17 cyclotron was used for [18F]fluo-
ride production and the radiosynthesis was carried out via
general automated methods using a GE FXFN radiofluorina-
tion module as previously reported in detail by our labora-
tory for the synthesis of [18F]4a,14 with only minor
modifications.
Briefly, to a reaction vessel containing reactive [18F]fluo-
ride was added 3 mg of 3c dissolved in 500 mL of CH3CN.
The reaction mixture was heated to 90 8C for 10 min, and
the reaction was quenched with 500 mL of H2O. The reac-
tion mixture was then purified via semipreparative HPLC
(20:80 CH3CN:H2O + 0.1 N ammonium formate + 1% for-
mic acid (pH 4), Semi-Prep LUNA C18(2) (250 mm 
10 mm, 10 mm, l = 254 nm)) at 6 mL/min. The major ra-
diochemical peak (tR = 13 min) was collected and formu-
lated as previously described.14 The formulated product was
analyzed by HPLC (30:70 CH3CN:H2O + 0.1 N ammonium
formate, Prodigy C18 ODS Prep column (250 mm 
4.6 mm, 10 mm, l = 254 nm)) at a flow of 3 mL/min.
HPLC analysis of formulated [18F]4c revealed high radio-
chemical (>99%) purities. Coinjection of the radioactive
product with an authentic standard of 4c under several dif-
ferent HPLC conditions (solvents, pH, wavelength; see Ta-
ble S2 in the Supplementary data) with different analytical
columns further established the identity of the radiotracer.
Specific activity was calculated at the end of synthesis from
the formulated product and was determined by integration of
the UV peak of an analytical HPLC chromatogram in com-
parison with standard solutions containing known concentra-
tions of 4c.
Ex vivo biodistribution
Ex vivo biodistribution studies in conscious male
Sprague–Dawley rats were conducted as previously de-
scribed by our group.32,33 All rats received *2.6 MBq of
[18F]4c in 0.3 mL of buffered saline via the tail vein and
were sacrificed by decapitation at either 5, 15, 30, or
60 min after injection (n = 1 per time point). The brains
were removed and regions of interest (striatum, thalamus,
hypothalamus, hippocampus, frontal cortex, rest of cortex,
cerebellum, rest of brain, as well as whole blood from the
trunk, bone, and heart) were excised, blotted, weighed, and
then counted for radioactivity (Fig. 3).
Metabolism studies
Following tail-vein injection of [18F]4c as described
above, whole blood was collected at various time points
from the trunk in a heparinized tube and centrifuged, and
the plasma was separated for metabolite analysis by HPLC
via the method of Hilton et al.,35 with minor modifications.
Briefly, rat plasma from each time point was directly loaded
onto a 5 mL HPLC injector loop and injected onto a capture
column (4.6 mm  20 mm) that was packed in-house with
OASIS HLB 30 mm (Waters, New Jersey). The capture col-
umn was eluted with 1% aqueous CH3CN (2 mL/min) for
3 min and then back-flushed (19:81 CH3CN:H2O + 0.1 N
ammonium formate, 2.0 mL/min) onto a Phenomenex
10 mm Luna C18 column (250 mm  4.6 mm). The column
effluents from both columns were monitored through a flow
detector (Bioscan Flow-Count) operated in coincidence
mode. Whole brain removed from a control rat and treated
with *1 MBq of [18F]4c and whole brain removed from a
rat sacrificed at 60 min after injection of [18F]4c in the tail
vein were individually homogenized with ice-cold 80%
ethanol and centrifuged as previously described by our labo-
ratory,36 prior to radio-HPLC analysis of the supernatant us-
ing the aforementioned method.
Supplementary data
Supplementary data for this article are available on the
journal Web site (canjchem.nrc.ca).
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